glp 1 super bowl commercial Serena Williams is facing heavy criticism after appearing in a LX promoting a GLP-1 weight-loss medication. Critics took to social media saying it was “wrong” or even “disgusting” to Ro makes Super Bowl debut

Ongoing and future largescale randomized trials will be critical for clarifying efficacy and safety for this use

Extreme caloric restriction while on semaglutide can lead to muscle loss, nutritional deficiencies, and metabolic adaptation that makes long-term weight maintenance harder

GLP-1 weight loss users significantly reduce their unit volume of food purchasing (-8.6%) and more revealingly of alcohol (-14.5%).[18] More recent, less accurate, survey research on GLP-1 weight-loss drug users from September 2023 suggests the following rank order of reported decreased consumption that features a big impact to the QSR and candy industries: Fast Food (77%) Pizza restaurants (74%) Confectionery (72%) Carbonated/sugary drinks (70%) Cookies/baked products (69%) Alcohol (66%)[19] Top foods where users report an increase in consumption: Fruits and vegetables 54% Weight-loss management foods (44%) Poultry and fish (38%)[20] GLP-1 drugs, unlike bariatric surgery, appear to have a strong effect on muting intrinsic desire for compulsive (and impulsive) eating and drinking

During the years-long tirzepatide and semaglutide shortages, which the FDA officially declared over in December and February, compounded GLP-1s became widely available through existing telehealth providers and startups that sprang up specifically to cash in on the new, lucrative health care niche